Avian influenza virus can spread in the farm by the faecal–oral and aerosol routes; can also be transmitted through fomites and flies may act as mechanical vectors. Highly Pathogenic Avian Influenza viruses have been found in the yolk and albumen of eggs from infected chickens, turkeys and quails. Complementary to biosecurity, vaccination has become the primary control measure used to minimise losses . The objective of this study was to evaluate the efficacy of Mefluvac H5 Plus 8 against circulating HPAI H5N6 and H5N8 viruses isolated in Vietnam, adopting 2 vaccination regimes.
Avian influenza viruses type A are members of the family Orthomyxoviridae, being structured with a negative-sense, single-strand, segmented genomic RNA. The outer viral coat is characterised by the presence of two important antigenic fractions, the hemagglutinin (HA) and neuraminidase (NA) proteins. Highly pathogenic avian influenza (HPAI) viruses can be originated from certain LPAI viruses while these are circulating in poultry flocks. HPAI viruses can cause mortality in 100% of the flock, and trigger epidemics that may spread rapidly, devastate the poultry industry and result in severe trade restrictions.
Animals: 3-week-old commercial chickens were purchased from a local farm in Vietnam with no avian influenza (AI) vaccination history. Before the experiments, birds were randomly checked for H5 antibodies and avian influenza virus (AIV) by RT-PCR test (10% of birds), obtaining negative results.
Vaccine: Mefluvac H5 Plus 8
Challenge viruses:
Used HI antigens: 3 weeks after each vaccine shot (at age of 6 and 9 weeks-old), all vaccinated birds were tested for antibody titers (H5 vaccine-homologous antigens).
Monitoring: Challenged chickens were monitored for 10 days after inoculation and scored for clinical signs in accordance with the WOAH guidelines.
Clinical protection and viral load reduction
The described figures (2A – 2B and 3A – 3B) concisely show i) the survival rate of vaccinated birds against virulent influenza viruses, and ii) the ability of reducing viral excretion; both considered important criteria when evaluating the efficacy of AI vaccines. The viral load was investigated by the analysis of oro-pharyngeal swabs after challenge.
Figure 2A and 2B – Challenge by HPAI H5N8 clade 2.3.4.4b at day 21 post-vaccination.
Figure 3A and 3B- Challenge by HPAI clase 2.3.4.4g at day 21 post-vaccination.
In the present study, we found that a vaccination regime with Mefluvac H5 Plus 8 inactivated vaccine triggered a strong immune response in experimental birds with homologous HI antibody titer of 6.6 log2 when used with 1-shot regime and 8.9 log2 when used with 2-times vaccination regime. After challenge with H5N8 clade 2.3.4.4b virus, Mefluvac H5 Plus 8 vaccine conferred a protective rate of 90% with both vaccination regimes: 1-shot and 2-shots. After challenge with H5N6 clade 2.3.4.4g virus, Mefluvac H5 Plus 8 vaccine conferred a protective rate of 90% for 1-shot vaccinated chickens and 100% protection for those birds receiving the 2-times vaccination regime.
References are available on request.
To learn more about vaccination against Avian Influenza please visit:
"*" indicates required fields
At Kemin we empower veterinarians and food producers across the globe to manage the risk against endemic and emerging diseases that compromise profitability and food security worldwide. With a strong awareness of the realities and trends shaping food animal production, we are proud to provide trusted vaccines building immunity for Transboundary Control, Respiratory Integrity, Immunocompetence and Food Safety. Click here to learn more about Kemin Biologics. Click here to learn more about our educational series.
At Kemin we empower veterinarians and food producers across the globe to manage the risk against endemic and emerging diseases that compromise profitability and food security worldwide. With a strong awareness of the realities and trends shaping food animal production, we are proud to provide trusted vaccines building immunity for Transboundary Control, Respiratory Integrity, Immunocompetence and Food Safety. Click here to learn more about Kemin Biologics. Click here to learn more about our educational series.
Notifications
Your Privacy Matters
It's your legal right to choose which information a website may store and have access to. With your permission, we and our third-party partners (19) store and/or access information on a device, such as unique identifiers in cookies and browsing data to collect and process personal data.
We and our partners do the following data processing:
Store and/or access information on a device, Advertising based on limited data and advertising measurement, Personalised content, content measurement, audience research, and services development
If you accept any or all of these, you will have agreed to this website's use of cookies for these purposes. You may also choose to refuse consent, but certain personalized features of the site won't be available to you.